https://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-plans-phase-3-ncp-trial-joins-btig-conference-75d76cafa23f022dPharma Surgeen2026-07-27T11:00:27.000ZOKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conferencehttps://www.pharmaradar360.com/article/veraxa-s-vxa-222-uses-one-molecule-to-address-two-tumor-antigens-aff976da3555de12Pharma Surgeen2026-07-27T11:00:00.000ZVERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigenshttps://www.pharmaradar360.com/article/okyo-pharma-plans-111-patient-phase-3-corneal-pain-trial-960786616eefabc2Pharma Surgeen2026-07-27T11:00:00.000ZOKYO Pharma plans 111-patient Phase 3 corneal pain trialhttps://www.pharmaradar360.com/article/bnp-paribas-adjusts-pt-on-west-pharmaceutical-services-to-459-from-447-maintains-e5664c0b1768a0c1Pharma Surgeen2026-07-27T10:50:52.000ZBNP Paribas Adjusts PT on West Pharmaceutical Services to $459 From $447, Maintains Outperform Ratinghttps://www.pharmaradar360.com/article/argenx-to-pick-up-autoimmune-biotech-forte-biosciences-for-2-2b-5fcd68a86f95712cPharma Surgeen2026-07-27T10:46:00.000ZArgenx to pick up autoimmune biotech Forte Biosciences for $2.2Bhttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-27T10:45:43.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/leadership-changes-at-legend-biotech-legn-576e7777e113ec0aPharma Surgeen2026-07-27T10:44:44.000ZLeadership Changes at Legend Biotech (LEGN)https://www.pharmaradar360.com/article/kura-oncology-reports-encouraging-phase-1a-data-for-darlifarnib-plus-cabozantini-5a7f72aa368d799cPharma Surgeen2026-07-27T10:40:00.000ZKura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinomahttps://www.pharmaradar360.com/article/legend-biotech-ceo-ying-huang-resigns-5dec7fe994f77283Pharma Surgeen2026-07-27T10:35:15.000ZLegend Biotech CEO Ying Huang Resignshttps://www.pharmaradar360.com/article/amazon-filters-eyes-global-pharma-market-at-record-breaking-ispe-singapore-2026-9954b0fc9506e387Pharma Surgeen2026-07-27T10:34:20.000ZAmazon Filters eyes global pharma market at record-breaking ISPE Singapore 2026https://www.pharmaradar360.com/article/magazine-made-in-the-usa-4a83b14aea62284bPharma Surgeen2026-07-27T10:32:02.000ZMagazine: Made in the USAhttps://www.pharmaradar360.com/article/fda-approves-first-otc-acetaminophen-naproxen-fixed-dose-combination-45a7a511e015ffdcPharma Surgeen2026-07-27T10:29:20.000ZFDA approves first OTC acetaminophen-naproxen fixed-dose combinationhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-expects-h1-2026-profit-attributable-rmb5-9-bln-rmb6-2-bln-78bb458ecfeb50d5Pharma Surgeen2026-07-27T10:26:03.000ZCSPC Pharmaceutical Expects H1 2026 Profit Attributable RMB5.9 Bln–RMB6.2 Blnhttps://www.pharmaradar360.com/article/argenx-pens-2-2bn-deal-to-buy-autoimmune-biotech-forte-ec02e16c0efa48b6Pharma Surgeen2026-07-27T10:23:07.000ZArgenx pens $2.2bn deal to buy autoimmune biotech Fortehttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-limited-provides-unaudited-consolidated-earnings-guida-f55849fdd080f2c0Pharma Surgeen2026-07-27T10:20:30.000ZCSPC Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2026D Stable Sales Growthhttps://www.pharmaradar360.com/article/thyroid-medication-described-as-subpotent-drug-recalled-by-fda-3e5d147e8b74eca8Pharma Surgeen2026-07-27T10:18:00.000ZThyroid medication described as 'subpotent drug' recalled by FDAhttps://www.pharmaradar360.com/article/outlook-therapeutics-wins-fda-approval-for-lytenava-in-wet-amd-61f9fb2061712f18Pharma Surgeen2026-07-27T10:17:01.000ZOutlook Therapeutics wins FDA approval for Lytenava in wet AMDhttps://www.pharmaradar360.com/article/5-stocks-that-created-fortunes-cmps-327-arwr-222-cgon-148-drts-182-elmd-86-6762879798ba79b6Pharma Surgeen2026-07-27T10:13:00.000Z5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%https://www.pharmaradar360.com/article/legend-biotech-announces-ceo-transition-appoints-alan-bash-interim-chief-executi-cf747abfe7eff102Pharma Surgeen2026-07-27T10:12:00.000ZLegend Biotech Announces CEO Transition, Appoints Alan Bash Interim Chief Executive Officerhttps://www.pharmaradar360.com/article/legend-biotech-ceo-ying-huang-steps-down-alan-bash-named-interim-aa272bb9fe0e6b7fPharma Surgeen2026-07-27T10:07:45.000ZLegend Biotech CEO Ying Huang steps down, Alan Bash named interimhttps://www.pharmaradar360.com/article/legend-biotech-legn-ceo-ying-huang-exits-as-board-appoints-interim-chief-7512a9223f8f60f9Pharma Surgeen2026-07-27T10:03:04.000ZLegend Biotech (LEGN) CEO Ying Huang exits as board appoints interim chiefhttps://www.pharmaradar360.com/article/legend-biotech-announces-ceo-transition-2836d2c166c2516bPharma Surgeen2026-07-27T10:00:00.000ZLegend Biotech Announces CEO Transitionhttps://www.pharmaradar360.com/article/puerto-rico-imports-3-254-billion-in-generic-drugs-and-faces-the-threat-of-tarif-af65b7b284f2ca8dPharma Surgeen2026-07-27T10:00:00.000ZPuerto Rico imports $3.254 billion in generic drugs and faces the threat of tariffs of up to 200%https://www.pharmaradar360.com/article/takeda-pharmaceutical-co-tak-shares-purchased-by-renaissance-technologies-llc-1b90d613ad707d25Pharma Surgeen2026-07-27T09:49:56.000ZTakeda Pharmaceutical Co. $TAK Shares Purchased by Renaissance Technologies LLChttps://www.pharmaradar360.com/article/working-for-ukhsa-b7a5672bf6c8e205Pharma Surgeen2026-07-27T09:47:20.000ZWorking for UKHSAhttps://www.pharmaradar360.com/article/renaissance-technologies-llc-has-52-55-million-stock-position-in-west-pharmaceut-d8f18be42c337273Pharma Surgeen2026-07-27T09:45:53.000ZRenaissance Technologies LLC Has $52.55 Million Stock Position in West Pharmaceutical Services, Inc. $WSThttps://www.pharmaradar360.com/article/rfk-jr-s-big-promise-to-ban-pharmaceutical-ads-is-in-the-slow-lane-74b6b1a818323117Pharma Surgeen2026-07-27T09:38:43.000ZRFK Jr.’s Big Promise to Ban Pharmaceutical Ads Is in the Slow Lanehttps://www.pharmaradar360.com/article/pharma-packaging-under-ppwr-safety-and-validation-demands-challenge-compliance-18bc7bd4deddc738Pharma Surgeen2026-07-27T09:28:34.000ZPharma packaging under PPWR: Safety and validation demands challenge compliancehttps://www.pharmaradar360.com/article/from-a-small-town-pledge-to-the-big-time-a-quest-to-turn-central-ohio-into-a-bio-8cbd9cdf7a50e1acPharma Surgeen2026-07-27T09:19:39.000ZFrom a small-town pledge to the big time: A quest to turn central Ohio into a biotech hubhttps://www.pharmaradar360.com/article/sei-investments-co-has-35-62-million-position-in-teva-pharmaceutical-industries-6b6d12f9a699d7eaPharma Surgeen2026-07-27T09:16:14.000ZSei Investments Co. Has $35.62 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/click-e-stock-samsung-epis-holdings-focus-on-new-drug-development-strategy-over-8a5daa69df0418f5Pharma Surgeen2026-07-27T08:55:00.000Z[Click e-Stock] "Samsung Epis Holdings: Focus on New Drug Development Strategy Over Short-Term Earnings... Target Price Lowered"https://www.pharmaradar360.com/article/benefiting-from-chinese-pharma-innovation-04277890893b0413Pharma Surgeen2026-07-27T08:49:09.000ZBenefiting from Chinese pharma innovationhttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327Pharma Surgeen2026-07-27T08:48:41.000ZDHSC: workforce management informationhttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-june-2026-794c237d7da5718fPharma Surgeen2026-07-27T08:48:02.000ZDHSC: workforce management information June 2026https://www.pharmaradar360.com/article/the-intelligent-laboratory-how-ai-automation-digital-science-are-transforming-ph-18f02e0c108ac326Pharma Surgeen2026-07-27T08:21:44.000ZThe Intelligent Laboratory: How AI, Automation & Digital Science Are Transforming Pharmaceutical Qualityhttps://www.pharmaradar360.com/article/korea-selects-manager-for-170-bil-phase-3-fund-moves-closer-to-1-tri-bio-megafun-e9a3e09b821aecc8Pharma Surgeen2026-07-27T08:19:45.000ZKorea selects manager for ₩170 bil. phase 3 fund, moves closer to ₩1 tri. bio megafundhttps://www.pharmaradar360.com/article/astrazeneca-achieves-revenues-of-15-4-billion-dollars-supported-by-the-growth-in-90a059b22372aa48Pharma Surgeen2026-07-27T08:19:36.000ZAstraZeneca achieves revenues of 15.4 billion dollars supported by the growth in pharmaceutical saleshttps://www.pharmaradar360.com/article/north-west-university-training-future-experts-in-pharmaceutical-sciences-cca3e5439967544bPharma Surgeen2026-07-27T08:18:53.000ZNorth-West University: Training future experts in pharmaceutical scienceshttps://www.pharmaradar360.com/article/2026-787608f8eb716b96Pharma Surgeen2026-07-27T08:16:31.000ZΓενόσημα Μαΐου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/aribio-and-forevernk-join-to-develop-next-gen-alzheimer-s-drugs-in-south-korea-c-b2995e50edaf6264Pharma Surgeen2026-07-27T08:13:00.000ZAribio and ForeverNK join to develop next-gen Alzheimer’s drugs in South Korea - CHOSUNBIZhttps://www.pharmaradar360.com/article/the-next-generation-of-pharmaceutical-blister-packs-8bfe5a8b79b279a2Pharma Surgeen2026-07-27T08:06:41.000ZThe next generation of pharmaceutical blister packshttps://www.pharmaradar360.com/article/first-aid-how-to-make-pension-funds-pay-for-biotech-1c17a4e10b3dc50ePharma Surgeen2026-07-27T07:47:11.000ZFIRST AID: How to make pension funds pay for Biotechhttps://www.pharmaradar360.com/article/clinical-trial-per-patient-cost-analytics-for-procurement-and-sponsor-strategy-2f8afe8be649f58ePharma Surgeen2026-07-27T07:45:45.000ZClinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategyhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-tak-stock-price-news-quote-and-history-f6907d9cbe0672a9Pharma Surgeen2026-07-27T07:44:28.000ZTakeda Pharmaceutical Company Limited (TAK) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/stopped-the-six-year-cost-of-trials-that-never-reached-the-finish-line-da3c16a87362ec33Pharma Surgeen2026-07-27T07:44:11.000ZStopped: The Six-Year Cost of Trials That Never Reached the Finish Linehttps://www.pharmaradar360.com/article/dimerix-asx-dxb-adds-a-phase-2-asset-and-secures-a-new-us-patent-has-its-biotech-f4dff9ac0958d53ePharma Surgeen2026-07-27T07:40:00.000ZDimerix (ASX:DXB) Adds a Phase 2 Asset and Secures a New US Patent—Has Its Biotech Pipeline Just Been Transformed?https://www.pharmaradar360.com/article/astrazeneca-s-q2-net-profit-hits-2-5b-amid-fallout-from-wainua-clinical-trial-fa-276820c8c2c4c7f0Pharma Surgeen2026-07-27T07:39:34.000ZAstraZeneca’s Q2 Net Profit Hits $2.5B Amid Fallout From Wainua Clinical Trial Failurehttps://www.pharmaradar360.com/article/korea-selects-manager-for-170-bil-phase-3-fund-moves-closer-to-1-tri-bio-megafun-4b5f37db56af7520Pharma Surgeen2026-07-27T07:22:46.000ZKorea selects manager for ₩170 bil. phase 3 fund, moves closer to ₩1 tri. bio megafundhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-31-report-data-to-week-30-26-july-2-382af7c5ca707f23Pharma Surgeen2026-07-27T07:18:18.000ZNational Norovirus and Rotavirus Report, week 31 report: data to week 30 (26 July 2026)https://www.pharmaradar360.com/article/the-small-cap-wrap-quarterlies-acquisitions-and-biotech-breakthroughs-9d6e1e4f86f2a32fPharma Surgeen2026-07-27T07:13:50.000ZThe Small Cap Wrap: Quarterlies, acquisitions and biotech breakthroughshttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-31-report-data-to-week-30-dat-a3fb4f87cd2afcf2Pharma Surgeen2026-07-27T07:04:24.000ZNational flu and COVID-19 surveillance report, week 31 report: data to week 30 (data up to 26 July 2026)https://www.pharmaradar360.com/article/denmark-s-foundation-fueled-biotech-boom-redraws-the-nordic-map-cf871b13881163f4Pharma Surgeen2026-07-27T07:04:19.000ZDenmark’s foundation‑fueled biotech boom redraws the Nordic maphttps://www.pharmaradar360.com/article/digital-and-intelligent-health-forum-wang-zunlong-building-new-benchmark-for-med-7d15031c5494f955Pharma Surgeen2026-07-27T07:02:24.000ZDigital and Intelligent Health Forum｜Wang Zunlong: Building new benchmark for medical data, AI integration in Xi'anhttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-d6972347e5f20166Pharma Surgeen2026-07-27T06:57:59.000ZChinese biotech overtakes AI as emerging-market growth tradehttps://www.pharmaradar360.com/article/argenx-to-acquire-forte-biosciences-for-2-2-billion-gains-fb102-antibody-6c77f73490b846a6Pharma Surgeen2026-07-27T06:50:53.000Zargenx to Acquire Forte Biosciences for $2.2 Billion, Gains FB102 Antibodyhttps://www.pharmaradar360.com/article/the-oral-revolution-in-inflammatory-skin-disease-what-povorcitinib-s-phase-3-des-5b6495fc290e8d44Pharma Surgeen2026-07-27T06:50:53.000ZThe Oral Revolution in Inflammatory Skin Disease: What Povorcitinib’s Phase 3 Design Reveals About the Next Wave of Dermatology Trialshttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-3c1e545ea0c4b0dePharma Surgeen2026-07-27T06:33:00.000ZChinese biotech overtakes AI as emerging-market growth tradehttps://www.pharmaradar360.com/article/pharmacyte-biotech-inc-pmcb-earnings-forecast-future-eps-revenue-growth-estimate-5e5d0b550fe0d746Pharma Surgeen2026-07-27T06:27:18.000ZPharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimateshttps://www.pharmaradar360.com/article/4519-t-fy2026-q2-earnings-call-chugai-pharmaceutical-q2-core-operating-profit-ri-60b871b288c379c8Pharma Surgeen2026-07-27T06:16:00.000Z[4519.T FY2026 Q2 Earnings Call] Chugai Pharmaceutical Q2 Core Operating Profit Rises 21% to ¥329.1 Billion as Overseas Blockbusters and New Drug Royalties Diversify Revenue Structurehttps://www.pharmaradar360.com/article/update-on-phase-iii-trial-of-ultomiris-in-adults-and-adolescents-with-thrombotic-643bcc52602696c6Pharma Surgeen2026-07-27T06:10:00.000ZUpdate on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplanthttps://www.pharmaradar360.com/article/korea-investment-partners-chosen-to-manage-phase-3-trial-fund-targeting-150-bill-6a2f1b2929204739Pharma Surgeen2026-07-27T06:07:31.000ZKorea Investment Partners Chosen to Manage 'Phase 3 Trial Fund' Targeting 150 Billion Wonhttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-f38dcdd85eaaae80Pharma Surgeen2026-07-27T05:56:00.000ZChinese Biotech Overtakes AI as Emerging-Market Growth Tradehttps://www.pharmaradar360.com/article/kolon-tissuegene-officially-apologized-to-shareholders-for-failing-to-achieve-it-75fd6ed6768bb82cPharma Surgeen2026-07-27T05:53:52.000ZKolon TissueGene officially apologized to shareholders for failing to achieve its goal in the firsthttps://www.pharmaradar360.com/article/cha-biotech-wins-1-7-mil-government-ai-project-for-cell-therapy-documentation-b0e60bd45cc6f33fPharma Surgeen2026-07-27T05:23:40.000ZCHA Biotech wins $1.7 mil. government AI project for cell therapy documentationhttps://www.pharmaradar360.com/article/etf-showdown-xbi-vs-pbe-which-biotech-fund-wins-eaa983bcff893e4cPharma Surgeen2026-07-27T05:00:55.000ZETF Showdown: XBI vs PBE, Which Biotech Fund Wins?https://www.pharmaradar360.com/article/la-aemps-primera-agencia-europea-que-participa-en-un-programa-de-pasantias-inter-ab34068b38aff1ddPharma Surgeen2026-07-27T05:00:40.000ZLa AEMPS, primera agencia europea que participa en un programa de pasantías internacionales con la Organización Panamericana de la Saludhttps://www.pharmaradar360.com/article/otsuka-receives-fda-approval-for-first-in-class-simtriyo-centanafadine-for-the-t-c33d573214541ac9Pharma Surgeen2026-07-27T04:59:30.000ZOtsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Olderhttps://www.pharmaradar360.com/article/k-bio-1-trillion-mega-fund-imminent-first-ever-phase-3-clinical-trial-fund-launc-bdcb6522e293e8b7Pharma Surgeen2026-07-27T04:47:00.000ZK-Bio 1 Trillion Mega Fund 'Imminent', 'First-Ever' Phase 3 Clinical Trial Fund Launch! : 경제 : JKNhttps://www.pharmaradar360.com/article/washington-house-passes-fda-bill-to-move-medicine-testing-beyond-animals-bd99d3e7ceba2056Pharma Surgeen2026-07-27T04:32:00.000ZWashington House passes FDA bill to move medicine testing beyond animalshttps://www.pharmaradar360.com/article/zhejiang-huakang-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-605077-95ead1ee67ac300cPharma Surgeen2026-07-27T04:19:18.000ZZhejiang Huakang Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:605077https://www.pharmaradar360.com/article/summit-merck-must-navigate-new-regulatory-terrain-in-china-first-cancer-landscap-cd45c263b6971f8dPharma Surgeen2026-07-27T04:10:37.000ZSummit, Merck must navigate new regulatory terrain in China-first cancer landscapehttps://www.pharmaradar360.com/article/lilly-abbvie-climb-aboard-in-vivo-car-t-train-but-safety-remains-a-hurdle-23c04a273cf96888Pharma Surgeen2026-07-27T04:04:03.000ZLilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlehttps://www.pharmaradar360.com/article/p840k-unregistered-cooking-oil-seized-in-pampanga-cidg-raids-san-fernando-shop-o-020ed2822fd3419ePharma Surgeen2026-07-27T03:26:53.000ZP840K Unregistered Cooking Oil Seized in Pampanga: CIDG Raids San Fernando Shop Over FDA Law Violationshttps://www.pharmaradar360.com/article/how-new-phase-3-psoriasis-data-for-zasocitinib-at-takeda-pharmaceutical-tse-4502-4af123f3399138eaPharma Surgeen2026-07-27T03:16:00.000ZHow New Phase 3 Psoriasis Data For Zasocitinib At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Storyhttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-4ddc4205b8e60898Pharma Surgeen2026-07-27T03:08:00.000ZChinese biotech overtakes AI as emerging-market growth tradehttps://www.pharmaradar360.com/article/ibrx-stock-rises-overnight-retail-traders-hunt-for-global-expansion-clues-ahead-2c3156530805b6a5Pharma Surgeen2026-07-27T03:00:00.000ZIBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conferencehttps://www.pharmaradar360.com/article/south-korea-taps-korea-investment-partners-to-launch-phase-3-trial-fund-chosunbi-df2b48106ae93a4fPharma Surgeen2026-07-27T03:00:00.000ZSouth Korea taps Korea Investment Partners to launch phase 3 trial fund - CHOSUNBIZhttps://www.pharmaradar360.com/article/korea-investment-partners-selected-as-manager-for-korea-s-first-phase-3-clinical-0ebfff5063169a52Pharma Surgeen2026-07-27T03:00:00.000ZKorea Investment Partners Selected as Manager for Korea's First 'Phase 3 Clinical Trial Specialized Fund'https://www.pharmaradar360.com/article/fda-advisory-no-2026-0805-public-health-warning-against-the-purchase-and-use-of-202961e5201e38fePharma Surgeen2026-07-27T02:32:01.000ZFDA Advisory No.2026-0805 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “OTC Natural Green Leaf Anti-Itch Cream 20g” - Food and Drug Administrationhttps://www.pharmaradar360.com/article/interview-the-eu-s-biotech-act-is-helpful-but-not-yet-the-solution-investors-say-a34caed5b005aa02Pharma Surgeen2026-07-27T02:26:46.000ZINTERVIEW: 'The EU’s Biotech Act is helpful, but not yet the solution,' investors sayhttps://www.pharmaradar360.com/article/hk-inno-n-s-k-cab-gains-ulcer-prevention-indication-achieving-six-p-cab-approval-4531603ab2bc4d3cPharma Surgeen2026-07-27T02:26:00.000ZHK inno.N's K-CAB Gains Ulcer Prevention Indication, Achieving Six P-CAB Approvals in South Koreahttps://www.pharmaradar360.com/article/fda-advisers-recommend-relaxing-us-rules-on-compounding-peptides-33818127deaf2bdcPharma Surgeen2026-07-27T02:10:41.000ZFDA advisers recommend relaxing US rules on compounding peptideshttps://www.pharmaradar360.com/article/otsuka-launches-pocari-sweat-ion-water-powder-stick-packet-to-make-500mleasy-wat-f9bcdda90a05ff88Pharma Surgeen2026-07-27T02:00:00.000ZOtsuka Launches POCARI SWEAT ION WATER Powder Stick Packet to Make 500mlEasy Water and Ion Replenishment for Day-to-Day Situations: Ideal for Use with Reusable Bottleshttps://www.pharmaradar360.com/article/hlb-pep-registers-antidiuretic-hormone-api-with-u-s-fda-c177529d79b76812Pharma Surgeen2026-07-27T01:02:39.000ZHLB Pep Registers Antidiuretic Hormone API with U.S. FDAhttps://www.pharmaradar360.com/article/gc-biopharma-files-for-phase-2-trial-of-covid-19-mrna-vaccine-targets-2028-appro-3cfb88e87175b8abPharma Surgeen2026-07-27T00:52:50.000ZGC Biopharma Files for Phase 2 Trial of COVID-19 mRNA Vaccine, Targets 2028 Approvalhttps://www.pharmaradar360.com/article/kolon-tissuegene-rebounds-as-investors-bet-phase-3-setback-priced-in-chosunbiz-ab3d382446c50f5ePharma Surgeen2026-07-27T00:52:00.000ZKolon TissueGene rebounds as investors bet phase 3 setback priced in - CHOSUNBIZhttps://www.pharmaradar360.com/article/chinese-biotech-is-stealing-the-emerging-market-trade-that-ai-dominated-for-two-26346641454d4999Pharma Surgeen2026-07-27T00:14:27.000ZChinese biotech is stealing the emerging market trade that AI dominated for two yearshttps://www.pharmaradar360.com/article/gc-green-cross-submits-ind-for-phase-2-clinical-trial-of-covid-19-mrna-vaccine-s-b1c8414dd2ac1ffbPharma Surgeen2026-07-27T00:07:36.000ZGC Green Cross Submits IND for Phase 2 Clinical Trial of COVID-19 mRNA Vaccine...Selected for Disease Control Agency Support Projecthttps://www.pharmaradar360.com/article/hk-inno-n-wins-sixth-k-cab-indication-leading-south-korea-s-p-cab-field-chosunbi-05fd70c25c27238bPharma Surgeen2026-07-27T00:03:00.000ZHK inno.N wins sixth K-CAB indication, leading South Korea’s P-CAB field - CHOSUNBIZhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-ff3d167da94fa807Pharma Surgeen2026-07-27T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-88027fda4653c0eaPharma Surgeen2026-07-27T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/otsuka-receives-fda-approval-for-first-in-class-simtriyo-centanafadine-for-the-t-34e7938624abe63aPharma Surgeen2026-07-27T00:00:00.000ZOtsuka Receives FDA Approval for First-in-Class SIMTRIYO (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Olderhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-65492df36614037aPharma Surgeen2026-07-27T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-f5d308fbb3ec7554Pharma Surgeen2026-07-27T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-1745d9ee93ef5ad6Pharma Surgeen2026-07-27T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-ee838d2227a73a4dPharma Surgeen2026-07-27T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-07d221ad2234d9f2Pharma Surgeen2026-07-27T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-7d8f7475fe865f1dPharma Surgeen2026-07-27T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-c6e197a0da6f8286Pharma Surgeen2026-07-27T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-3b145c4c404c04bdPharma Surgeen2026-07-27T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-801444e85d384093Pharma Surgeen2026-07-27T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-5e6ef0e88a69ce16Pharma Surgeen2026-07-27T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-be5008e326271f88Pharma Surgeen2026-07-27T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-4161b618e4f03249Pharma Surgeen2026-07-27T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-5ed6ae332bb7ae6aPharma Surgeen2026-07-27T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-e254bdeaee59cf23Pharma Surgeen2026-07-27T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-03e180a51f4945d0Pharma Surgeen2026-07-27T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/medicare-and-medicaid-programs-quarterly-listing-of-program-issuances-april-thro-abab6c91c8e83f88Pharma Surgeen2026-07-27T00:00:00.000ZMedicare and Medicaid Programs; Quarterly Listing of Program Issuances-April Through June 2026https://www.pharmaradar360.com/article/medicare-program-approved-renewal-of-deeming-authority-of-the-national-committee-a630dfc206cf5813Pharma Surgeen2026-07-27T00:00:00.000ZMedicare Program; Approved Renewal of Deeming Authority of the National Committee for Quality Assurance (NCQA) for Medicare Advantage Health Maintenance Organizations and Preferred Provider Organizationshttps://www.pharmaradar360.com/article/proposed-information-collection-activity-mental-health-assessment-form-and-onsit-f26ea386d7cc7efcPharma Surgeen2026-07-27T00:00:00.000ZProposed Information Collection Activity; Mental Health Assessment Form and Onsite Health Intervention Formhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-6cac63d3395a9408Pharma Surgeen2026-07-27T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-855dbe1d11f97a88Pharma Surgeen2026-07-27T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-a07a07a2e6a10cf7Pharma Surgeen2026-07-27T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Active Noise Attenuation System for Infant Incubatorshttps://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-non-medic-c008d0c28d80785aPharma Surgeen2026-07-27T00:00:00.000ZMedical Devices; Gastroenterology-Urology Devices; Classification of the Non-Medicated Topical Formulation for Treatment of Erectile Dysfunctionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-6a9fe8ab160a10edPharma Surgeen2026-07-27T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Radioactive Drug Research Committeeshttps://www.pharmaradar360.com/article/vaginal-estrogen-application-techniques-for-prevention-of-urinary-tract-infectio-648f406cf56d041ePharma Surgeen2026-07-27T00:00:00.000ZVaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial.https://www.pharmaradar360.com/article/impact-of-international-travel-on-clinical-outcomes-of-mpox-cases-in-jeddah-saud-bfe9ce158b293109Pharma Surgeen2026-07-27T00:00:00.000ZImpact of International Travel on Clinical Outcomes of Mpox Cases in Jeddah, Saudi Arabia: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/allopurinol-induced-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-f60ff0c089b9ceefPharma Surgeen2026-07-27T00:00:00.000ZAllopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Published Evidence From Indiahttps://www.pharmaradar360.com/article/evaluation-of-the-dietary-quality-of-selected-public-university-and-private-hosp-615a6e4b513bc756Pharma Surgeen2026-07-27T00:00:00.000ZEvaluation of the dietary quality of selected public, university, and private hospital menushttps://www.pharmaradar360.com/article/the-effectiveness-of-electric-and-manual-toothbrush-use-on-the-loe-and-silness-p-3307196a36e2951dPharma Surgeen2026-07-27T00:00:00.000ZThe Effectiveness of Electric and Manual Toothbrush Use on the Loe and Silness Plaque Index Among Students with Intellectual Disabilities at SLBN Branjangan Jember, East Java, Indonesiahttps://www.pharmaradar360.com/article/colonic-perforation-secondary-to-entamoeba-histolytica-infection-a-case-report-a7a3e0e672b11e98Pharma Surgeen2026-07-27T00:00:00.000ZColonic Perforation Secondary to Entamoeba Histolytica Infection: A Case Reporthttps://www.pharmaradar360.com/article/the-viral-legacy-in-diabetic-ketoacidosis-impact-of-concurrent-respiratory-viral-b889283e836c26bePharma Surgeen2026-07-27T00:00:00.000ZThe Viral Legacy in Diabetic Ketoacidosis: Impact of Concurrent Respiratory Viral Infections on Acute Severity and Long-Term Glycemic Control in Children With Newly Diagnosed Type 1 Diabeteshttps://www.pharmaradar360.com/article/comparison-of-the-effect-of-pyridostigmine-and-sugammadex-on-emergence-delirium-491c37e8c02e46f0Pharma Surgeen2026-07-27T00:00:00.000ZComparison of the Effect of Pyridostigmine and Sugammadex on Emergence Delirium in Pediatric Patients Undergoing Strabismus Surgery: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/self-reported-neck-and-low-back-disability-in-female-show-jumping-riders-a-cross-18bc811e9b0d3fdcPharma Surgeen2026-07-27T00:00:00.000ZSelf-Reported Neck and Low Back Disability in Female Show Jumping Riders: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/complicated-versus-uncomplicated-acute-appendicitis-clinical-characteristics-dia-5c211b3e64a429b1Pharma Surgeen2026-07-27T00:00:00.000ZComplicated versus uncomplicated acute appendicitis: clinical characteristics, diagnostic scores, surgical management, and outcomes in a tertiary hospital in Mogadishu, Somaliahttps://www.pharmaradar360.com/article/cohort-profile-guangdong-pharmaceutical-university-occupational-health-cohort-in-14213c93414532adPharma Surgeen2026-07-27T00:00:00.000ZCohort profile: Guangdong Pharmaceutical University Occupational Health Cohort in Xishan Coal Electricity Group (GDPU-OHC)https://www.pharmaradar360.com/article/stathmin-in-human-health-and-diseases-from-cytoskeletal-dynamics-to-clinical-imp-e5b9df1c3a674330Pharma Surgeen2026-07-27T00:00:00.000ZStathmin in human health and diseases: from cytoskeletal dynamics to clinical implicationshttps://www.pharmaradar360.com/article/a-full-cycle-integrated-management-model-for-esophageal-cancer-in-county-health-5e49719e86ea4e6aPharma Surgeen2026-07-27T00:00:00.000ZA full-cycle integrated management model for esophageal cancer in county health systems: effects on care processes, clinical outcomes, quality of life, and cost-utilityhttps://www.pharmaradar360.com/article/effects-of-aged-black-garlic-abg10-on-lipoprotein-subclass-composition-in-grade-49f256dbc7d48da8Pharma Surgeen2026-07-27T00:00:00.000ZEffects of aged black garlic (ABG10+®) on lipoprotein subclass composition in Grade I hypertension: a randomized, triple-blind controlled trial with sex-stratified sequential allocationhttps://www.pharmaradar360.com/article/from-clinical-phenotypes-to-molecular-precision-multimodal-biomarkers-for-progre-2c7255af82c8fcfePharma Surgeen2026-07-27T00:00:00.000ZFrom clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsyhttps://www.pharmaradar360.com/article/macrohormones-in-endocrinology-prevalence-clinical-impact-and-diagnostic-approac-f4b14036f36f0590Pharma Surgeen2026-07-27T00:00:00.000ZMacrohormones in endocrinology: prevalence, clinical impact, and diagnostic approacheshttps://www.pharmaradar360.com/article/from-hansch-to-diffusion-models-data-algorithms-and-the-uneven-progress-of-compu-e66fcc0247bc3951Pharma Surgeen2026-07-27T00:00:00.000ZFrom Hansch to Diffusion Models: Data, Algorithms, and the Uneven Progress of Computational Drug Discoveryhttps://www.pharmaradar360.com/article/the-effect-of-dietary-fiber-based-on-fermentability-and-viscosity-on-the-gut-mic-2d07230a27aa578cPharma Surgeen2026-07-27T00:00:00.000ZThe effect of dietary fiber based on fermentability and viscosity on the gut microbiome composition in chronic kidney disease: a systematic review of experimental and clinical trialshttps://www.pharmaradar360.com/article/automated-modeling-of-population-pharmacokinetic-models-using-nlmixr2auto-a-clin-5894f4bdf4fda911Pharma Surgeen2026-07-27T00:00:00.000ZAutomated modeling of population pharmacokinetic models using nlmixr2auto: a clinical trial and real-world data studyhttps://www.pharmaradar360.com/article/past-month-nicotine-versus-thc-e-cigarette-use-and-moderate-to-severe-anxiety-sy-431cd6a1e034d278Pharma Surgeen2026-07-27T00:00:00.000ZPast-Month Nicotine versus THC E-Cigarette Use and Moderate-to-Severe Anxiety Symptoms Among U.S. Adults: A Cross-Sectional Analysis of the 2024 National Survey on Drug Use and Healthhttps://www.pharmaradar360.com/article/machine-learning-based-identification-of-drug-resistant-pathogen-infection-in-pa-e13ef99d5cd2e945Pharma Surgeen2026-07-27T00:00:00.000ZMachine Learning–Based Identification of Drug-Resistant Pathogen Infection in Patients With Sepsis: A Multicenter Cohort Studyhttps://www.pharmaradar360.com/article/clinical-decision-making-approach-and-associated-factors-among-nurses-working-in-7c369fc3bc5ebaa3Pharma Surgeen2026-07-27T00:00:00.000ZClinical Decision Making approach and Associated Factors among Nurses Working in South West Shoa Zone Hospitals Oromia Regional State, Ethiopia, 2023: A cross-sectional studyhttps://www.pharmaradar360.com/article/an-epithelial-mesenchymal-transition-related-gene-signature-predicts-prognosis-i-452b8eb8d7cb8035Pharma Surgeen2026-07-27T00:00:00.000ZAn epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancerhttps://www.pharmaradar360.com/article/magnetic-targeting-systems-for-cancer-therapy-bridging-magnet-design-advanced-th-c859edaebf689a25Pharma Surgeen2026-07-27T00:00:00.000ZMagnetic targeting systems for cancer therapy: bridging magnet design, advanced therapeutics, and clinical translationhttps://www.pharmaradar360.com/article/translational-laboratory-medicine-and-interdisciplinary-biomarker-discovery-in-s-968dc022b15cbc38Pharma Surgeen2026-07-27T00:00:00.000ZTranslational laboratory medicine and interdisciplinary biomarker discovery in sepsis: bridging molecular insights and clinical decision-makinghttps://www.pharmaradar360.com/article/risk-outcome-assessment-with-novel-long-t-itc-complex-and-high-sensitivity-tropo-baf27a3c0c9a910cPharma Surgeen2026-07-27T00:00:00.000ZRisk outcome assessment with novel long-T ITC complex and high sensitivity troponin I and T in patients with suspected acute coronary syndromes: MERITnI substudyhttps://www.pharmaradar360.com/article/solvent-matters-a-call-for-rigorous-consideration-of-organic-co-solvents-in-drug-d81503ad02fac344Pharma Surgeen2026-07-27T00:00:00.000ZSolvent Matters: A Call for Rigorous Consideration of Organic Co-solvents in Drug-target Interaction Studieshttps://www.pharmaradar360.com/article/effects-of-reflection-through-action-on-collaborative-clinical-reasoning-skills-50a5b1d4f2ddc0f3Pharma Surgeen2026-07-27T00:00:00.000ZEffects of reflection-through-action on collaborative clinical reasoning skills in an emergency dental simulationhttps://www.pharmaradar360.com/article/perspectives-of-turkish-family-physicians-in-istanbul-about-e-cigarettes-as-smok-09be4eb1e3e749a9Pharma Surgeen2026-07-27T00:00:00.000ZPerspectives of Turkish family physicians in Istanbul about e-cigarettes as smoking cessation aids: a cross-sectional survey studyhttps://www.pharmaradar360.com/article/sample-size-assumptions-timing-asymmetries-and-endpoint-selection-limit-the-inte-6f46780006974db8Pharma Surgeen2026-07-27T00:00:00.000ZSample size assumptions, timing asymmetries, and endpoint selection limit the interpretability of the CLEANSE hemoadsorption trial in septic shockhttps://www.pharmaradar360.com/article/ai-integrated-nanomaterial-based-biosensors-for-biomedical-diagnostics-engineeri-a09efa867f015986Pharma Surgeen2026-07-27T00:00:00.000ZAI-integrated nanomaterial-based biosensors for biomedical diagnostics: engineering design, signal processing, and clinical translationhttps://www.pharmaradar360.com/article/minocycline-for-acute-basilar-artery-occlusion-stroke-undergoing-endovascular-tr-6859cce6e429787fPharma Surgeen2026-07-27T00:00:00.000ZMinocycline for acute basilar artery occlusion stroke undergoing endovascular treatment: a randomized, evaluator-blinded, open-label, pilot trialhttps://www.pharmaradar360.com/article/clinical-and-pathological-characteristics-immune-microenvironment-and-survival-a-c357a043fcbe6e10Pharma Surgeen2026-07-27T00:00:00.000ZClinical and pathological characteristics, immune microenvironment, and survival analysis of molecular subtypes of surgically resected small cell lung cancerhttps://www.pharmaradar360.com/article/the-convergence-trial-protocol-a-phase-ii-iii-trial-for-conversion-surgery-for-g-6e803c5e07a26adfPharma Surgeen2026-07-27T00:00:00.000ZThe CONVERGENCE trial protocol: a phase II/III trial for conversion surgery for gastric cancer with peritoneal metastaseshttps://www.pharmaradar360.com/article/influencing-factors-and-individualized-intervention-strategies-for-inadequate-bo-6f13f0b36e564db3Pharma Surgeen2026-07-27T00:00:00.000ZInfluencing factors and individualized intervention strategies for inadequate bowel preparation before colonoscopy in high-risk populations: a review based on the clinical practice of painless colonoscopy in Chinahttps://www.pharmaradar360.com/article/national-trends-in-cardiovascular-deaths-with-concurrent-accidental-drug-poisoni-315735283f6f6281Pharma Surgeen2026-07-27T00:00:00.000ZNational trends in cardiovascular deaths with concurrent accidental drug poisoning coding in the United States: a 22-year analysis of the CDC WONDER database (1999–2020)https://www.pharmaradar360.com/article/convergence-of-ancient-wisdom-and-modern-healing-the-synergistic-potential-of-yo-87e71f4292ad6ae2Pharma Surgeen2026-07-27T00:00:00.000ZConvergence of Ancient Wisdom and Modern Healing: The Synergistic Potential of Yoga and Ayurveda in Contemporary Evidence-based Medicinehttps://www.pharmaradar360.com/article/what-is-your-diagnosis-cervical-mass-in-a-timber-rattlesnake-8ac84827f70fd2b9Pharma Surgeen2026-07-27T00:00:00.000ZWhat Is Your Diagnosis? Cervical Mass in a Timber Rattlesnakehttps://www.pharmaradar360.com/article/clinical-and-sociodemographic-characteristics-of-young-people-with-early-psychos-4b82c3e96f9b405ePharma Surgeen2026-07-27T00:00:00.000ZClinical and Sociodemographic Characteristics of Young People With Early Psychosis: Comparing Cannabis Users and Non‐Users in a Specialized Early Intervention Settinghttps://www.pharmaradar360.com/article/evaluating-ai-demand-forecasting-models-for-manufacturing-planning-in-the-pharma-881cfd2d9c7c0e90Pharma Surgeen2026-07-27T00:00:00.000ZEvaluating AI demand forecasting models for manufacturing planning in the pharmaceutical sector using AHP and TOPSIS: evidence from literature and a Moroccan case studyhttps://www.pharmaradar360.com/article/rapid-reinitiation-of-clozapine-after-recent-discontinuation-3e2e3d794458a6dfPharma Surgeen2026-07-27T00:00:00.000ZRapid Reinitiation of Clozapine After Recent Discontinuationhttps://www.pharmaradar360.com/article/predicting-metabolic-adverse-effects-of-lithium-in-bipolar-disorder-b64129ba54d193bePharma Surgeen2026-07-27T00:00:00.000ZPredicting Metabolic Adverse Effects of Lithium in Bipolar Disorderhttps://www.pharmaradar360.com/article/impact-of-system-efficiency-on-out-of-hospital-cardiac-arrest-outcomes-and-hospi-55f5d57325cd0bbbPharma Surgeen2026-07-27T00:00:00.000ZImpact of system efficiency on out-of-hospital cardiac arrest outcomes and hospital stay: an observational study from Lombardia CARehttps://www.pharmaradar360.com/article/a-whole-word-computational-algorithm-for-phonological-error-scoring-differentiat-5970a5ca473159dfPharma Surgeen2026-07-27T00:00:00.000ZA whole-word computational algorithm for phonological error scoring: Differentiating children with developmental language disorder, hearing impairment, and typical developmenthttps://www.pharmaradar360.com/article/effectiveness-of-liquorice-gel-as-an-adjunct-to-non-surgical-periodontal-therapy-68ebd34172bb6ce4Pharma Surgeen2026-07-27T00:00:00.000ZEffectiveness of liquorice gel as an adjunct to non-surgical periodontal therapy in chronic periodontitis: a randomized controlled, clinical and microbiological trialhttps://www.pharmaradar360.com/article/intravenous-aprepitant-for-prevention-of-postoperative-nausea-and-vomiting-in-ad-a6f08015f254c157Pharma Surgeen2026-07-27T00:00:00.000ZIntravenous aprepitant for prevention of postoperative nausea and vomiting in adults at moderate-to-high risk in China: a multicenter, randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/therapeutic-potential-of-commiphora-species-in-wound-healing-a-systematic-review-948c84a485cb79f2Pharma Surgeen2026-07-27T00:00:00.000ZTherapeutic Potential of Commiphora Species in Wound Healing: A Systematic Review of Clinical Evidencehttps://www.pharmaradar360.com/article/correction-the-bidirectionality-of-lawyer-reporting-bias-in-disproportionality-a-a42baa76f0331733Pharma Surgeen2026-07-27T00:00:00.000ZCorrection: The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysishttps://www.pharmaradar360.com/article/physiologically-based-pharmacokinetic-modeling-of-vedolizumab-in-healthy-adults-2ea879e711ffa2b8Pharma Surgeen2026-07-27T00:00:00.000ZPhysiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Diseasehttps://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-of-rosa-robotic-assisted-total-knee-arthropla-377c27bc280518dcPharma Surgeen2026-07-27T00:00:00.000ZClinical and radiographic outcomes of ROSA robotic-assisted total knee arthroplasty: a retrospective comparison of anatomic (persona) versus symmetric (vanguard) implant designshttps://www.pharmaradar360.com/article/biofilm-disruption-by-citronellol-and-geraniol-against-clinical-uropathogenic-ps-27dfc60d36b2df6bPharma Surgeen2026-07-27T00:00:00.000ZBiofilm disruption by citronellol and geraniol against clinical uropathogenic Pseudomonas aeruginosa: an integrated in vitro and in silico investigationhttps://www.pharmaradar360.com/article/letter-to-the-editor-a-kaleidoscopic-autoimmune-syndrome-covas-following-covid-1-d1a08099171925c3Pharma Surgeen2026-07-27T00:00:00.000ZLetter to the Editor: “A kaleidoscopic autoimmune syndrome (COVAS) following COVID-19 exposure”https://www.pharmaradar360.com/article/evaluation-of-serum-chromium-nickel-and-magnesium-levels-in-patients-with-type-2-cd111f238efb3a6bPharma Surgeen2026-07-27T00:00:00.000ZEvaluation of serum chromium, nickel, and magnesium levels in patients with type 2 diabetes mellitus and periodontitis: A cross-sectional studyhttps://www.pharmaradar360.com/article/technique-dependent-differences-in-internal-adaptation-porosity-and-degree-of-co-b030e2831c6b0edaPharma Surgeen2026-07-27T00:00:00.000ZTechnique-dependent differences in internal adaptation, porosity and degree of conversion of short fibre-reinforced composite restorations in deep MOD cavitieshttps://www.pharmaradar360.com/article/skin-keratin-correlates-with-bone-and-tendon-collagen-quality-a-proof-of-concept-76be41121023a713Pharma Surgeen2026-07-27T00:00:00.000ZSkin keratin correlates with bone and tendon collagen quality: a proof-of-concept clinical study using FTIR spectroscopy in shoulder arthroplasty patientshttps://www.pharmaradar360.com/article/the-pivotal-role-of-macrophages-in-tumorigenesis-and-pioneering-cancer-immunothe-0121b60a1472778fPharma Surgeen2026-07-27T00:00:00.000ZThe pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiershttps://www.pharmaradar360.com/article/age-sex-and-segment-specific-myocardial-t1-and-t2-reference-values-in-a-healthy-026edf9b8016739bPharma Surgeen2026-07-27T00:00:00.000ZAge-, sex-, and segment-specific myocardial T1 and T2 reference values in a healthy cohort: a prospective single-center studyhttps://www.pharmaradar360.com/article/emerging-trends-in-artificial-intelligence-driven-drug-discovery-balancing-chemi-ecb9817948defcd5Pharma Surgeen2026-07-27T00:00:00.000ZEmerging Trends in Artificial Intelligence‐Driven Drug Discovery: Balancing Chemical Design and Pharmacological Properties for Cancer Therapyhttps://www.pharmaradar360.com/article/successful-co-administration-of-secukinumab-and-dupilumab-in-a-patient-with-psor-309122d66c0b8fe9Pharma Surgeen2026-07-27T00:00:00.000ZSuccessful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitishttps://www.pharmaradar360.com/article/fitness-to-stand-trial-in-india-demographic-clinical-and-legal-profiles-of-court-189ef1962952c886Pharma Surgeen2026-07-27T00:00:00.000ZFitness to Stand Trial in India: Demographic, Clinical, and Legal Profiles of Court‐Referred Defendantshttps://www.pharmaradar360.com/article/preparation-and-characterization-of-scp-ph-scp-responsive-kaolin-containing-pect-b2c940c5ef1dcaf6Pharma Surgeen2026-07-27T00:00:00.000ZPreparation and Characterization of <scp>pH</scp> ‐Responsive Kaolin‐Containing Pectin/Poly(Acrylic Acid) <scp>IPN</scp> Hydrogel for Potential Colon‐Targeted Drug Deliveryhttps://www.pharmaradar360.com/article/kolon-tissuegene-apologizes-for-tg-c-clinical-trial-failure-vows-to-regain-honor-c0b181bd72af26fcPharma Surgeen2026-07-26T23:50:33.000ZKolon TissueGene Apologizes for TG-C Clinical Trial Failure... Vows to Regain Honor as World's First Therapyhttps://www.pharmaradar360.com/article/syntara-secures-fda-support-for-amsulostat-phase-2b-trial-in-myelofibrosis-and-r-41630ca2031e1067Pharma Surgeen2026-07-26T23:49:06.000ZSyntara Secures FDA Support for Amsulostat Phase 2b Trial in Myelofibrosis and Raises $8M to Fuel Clinical Pipeline Growthhttps://www.pharmaradar360.com/article/syntara-s-fda-backed-amsulostat-advances-to-phase-2b-myelofibrosis-trial-as-clin-f062cb6743c38bc1Pharma Surgeen2026-07-26T23:49:06.000ZSyntara's FDA-Backed Amsulostat Advances to Phase 2b Myelofibrosis Trial as Clinical Pipeline Delivers Multiple Data Catalystshttps://www.pharmaradar360.com/article/grand-pharmaceutical-group-limited-revenue-breakdown-fwb-mx6a-4bb9ccdd906ef8b9Pharma Surgeen2026-07-26T23:48:58.000ZGrand Pharmaceutical Group Limited Revenue Breakdown – FWB:MX6Ahttps://www.pharmaradar360.com/article/tien-liang-biotech-co-ltd-revenue-breakdown-tpex-4127-e40923e62cbaa2d7Pharma Surgeen2026-07-26T23:48:45.000ZTien Liang Biotech Co., Ltd. Revenue Breakdown – TPEX:4127https://www.pharmaradar360.com/article/the-paradox-of-the-kosdaq-promotion-relegation-system-2-technology-transfer-crit-bf79cee1d5e0c487Pharma Surgeen2026-07-26T23:31:00.000Z[The Paradox of the KOSDAQ Promotion/Relegation System]② Technology Transfer Criteria? ...May Encourage Premature Sell-Offshttps://www.pharmaradar360.com/article/crystalys-therapeutics-tacks-on-130m-for-pivotal-tests-of-gout-drug-1b46ad302ca3080ePharma Surgeen2026-07-26T23:28:46.000ZCrystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drughttps://www.pharmaradar360.com/article/dimerix-to-present-phase-3-fsgs-trial-update-and-acute-kidney-injury-program-at-66097df42177e45ePharma Surgeen2026-07-26T23:15:02.000ZDimerix to Present Phase 3 FSGS Trial Update and Acute Kidney Injury Program at TechKnow Invest Conferencehttps://www.pharmaradar360.com/article/patrys-reformulates-proven-quetiapine-drug-for-rapid-injectable-treatment-of-del-32e982bbb0715700Pharma Surgeen2026-07-26T23:15:02.000ZPatrys Reformulates Proven Quetiapine Drug for Rapid Injectable Treatment of Delirium in ICU Patientshttps://www.pharmaradar360.com/article/takeda-tse-4502-stock-looks-below-fair-value-while-broader-checks-stay-mixed-2e18f3323a95f107Pharma Surgeen2026-07-26T23:12:14.000ZTakeda (TSE:4502) Stock Looks Below Fair Value While Broader Checks Stay Mixedhttps://www.pharmaradar360.com/article/fred-ramsdell-biotech-is-leading-innovative-science-not-universities-12e5a2fea629dcc9Pharma Surgeen2026-07-26T23:01:00.000ZFred Ramsdell: Biotech is ‘leading innovative science, not universities’https://www.pharmaradar360.com/article/samchundang-tempers-fda-hope-as-korea-weighs-disclosure-rules-and-gmp-woes-chosu-62ee68567817c8bfPharma Surgeen2026-07-26T21:01:00.000ZSamchundang tempers FDA hope as Korea weighs disclosure rules and GMP woes - CHOSUNBIZhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-anhui-sunhere-pharmaceutical-excipients-co-ltd-class-a-a610d3f35d283cf8Pharma Surgeen2026-07-26T20:11:00.000ZPrice to sales forward of Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A – SZSE:300452https://www.pharmaradar360.com/article/cyclospora-outbreak-former-fda-food-safety-chief-says-skip-bagged-salads-96f7e45ee941f14fPharma Surgeen2026-07-26T20:09:00.000ZCyclospora Outbreak: Former FDA Food Safety Chief Says Skip Bagged Saladshttps://www.pharmaradar360.com/article/jiangxi-tianxin-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-603235-4659ef89fc7f499ePharma Surgeen2026-07-26T19:44:15.000ZJiangXi Tianxin Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:603235https://www.pharmaradar360.com/article/price-to-earnings-forward-of-enwei-pharmaceutical-co-ltd-class-a-szse-301331-bb34610971971cefPharma Surgeen2026-07-26T19:38:19.000ZPrice to earnings forward of Enwei Pharmaceutical Co., Ltd. Class A – SZSE:301331https://www.pharmaradar360.com/article/idg-seizes-php-700k-unregistered-korean-luncheon-meat-in-cebu-ff12728aad4ff041Pharma Surgeen2026-07-26T19:24:22.000ZIDG SEIZES PHP 700K UNREGISTERED KOREAN LUNCHEON MEAT IN CEBUhttps://www.pharmaradar360.com/article/laminar-pharma-completes-pivotal-phase-2b-3-trial-of-lam561-in-newly-diagnosed-g-7ec4d0a0a229f392Pharma Surgeen2026-07-26T19:18:48.000ZLaminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastomahttps://www.pharmaradar360.com/article/prnaf-sec-filings-alterity-therapeutics-ltd-10-k-10-q-8-k-forms-e97c85a414092859Pharma Surgeen2026-07-26T19:14:11.000ZPRNAF SEC Filings - ALTERITY THERAPEUTICS LTD 10-K, 10-Q, 8-K Formshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-anhui-sunhere-pharmaceutical-excipients-co-l-8c074977e6b4f09dPharma Surgeen2026-07-26T18:50:40.000ZEnterprise value to EBIT forward of Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A – SZSE:300452https://www.pharmaradar360.com/article/nunzia-pharmaceutical-corporation-revenue-breakdown-otc-nunz-4cb16e4d0d6d6121Pharma Surgeen2026-07-26T18:48:04.000ZNunzia Pharmaceutical Corporation Revenue Breakdown – OTC:NUNZhttps://www.pharmaradar360.com/article/fda-suspends-licences-of-three-mumbai-hotels-over-food-safety-breaches-7081b6571a4e146aPharma Surgeen2026-07-26T18:27:49.000ZFDA suspends licences of three Mumbai hotels over food safety breacheshttps://www.pharmaradar360.com/article/pune-fda-raids-butter-shortage-looms-for-restaurants-5992c00b01ebcd7cPharma Surgeen2026-07-26T18:26:03.000ZPune FDA Raids: Butter Shortage Looms for Restaurantshttps://www.pharmaradar360.com/article/the-trump-administration-s-best-healthcare-idea-isn-t-the-one-getting-attention-cd01ac00b3a36a67Pharma Surgeen2026-07-26T18:22:26.000ZThe Trump Administration’s Best Healthcare Idea Isn’t the One Getting Attentionhttps://www.pharmaradar360.com/article/compounded-glp-1-drugs-creating-concern-among-doctors-and-fda-e82507328de27c02Pharma Surgeen2026-07-26T18:17:07.000ZCompounded GLP-1 drugs creating concern among doctors and FDAhttps://www.pharmaradar360.com/article/is-the-vaneck-pharmaceutical-etf-or-state-street-health-care-etf-the-better-buy-e10ac2d1a940bca5Pharma Surgeen2026-07-26T18:01:00.000ZIs the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?https://www.pharmaradar360.com/article/why-universal-gene-synthesis-screening-protects-american-biotech-fba4b2d1017669b8Pharma Surgeen2026-07-26T17:40:52.000ZWhy Universal Gene Synthesis Screening Protects American Biotechhttps://www.pharmaradar360.com/article/is-the-vaneck-pharmaceutical-etf-or-state-street-health-care-etf-the-better-buy-707d5123a5bf69aePharma Surgeen2026-07-26T17:21:00.000ZIs the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?https://www.pharmaradar360.com/article/chugai-pharmaceutical-tse-4519-stock-net-margin-strength-challenges-cost-pressur-f1b6fd441b9fa49bPharma Surgeen2026-07-26T16:30:55.000ZChugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure Concernshttps://www.pharmaradar360.com/article/fda-panel-supports-broadening-access-to-peptides-popular-on-the-gray-market-39f76fd9a9bafee6Pharma Surgeen2026-07-26T16:00:00.000ZFDA panel supports broadening access to peptides popular on the gray markethttps://www.pharmaradar360.com/article/fda-denies-cooking-oil-sampling-rumor-512a521971a6f838Pharma Surgeen2026-07-26T16:00:00.000ZFDA denies cooking oil sampling rumorhttps://www.pharmaradar360.com/article/aspen-positions-itself-as-key-african-supplier-of-merck-hiv-pill-e918a9517c3dabd3Pharma Surgeen2026-07-26T15:19:04.000ZAspen positions itself as key African supplier of Merck HIV pillhttps://www.pharmaradar360.com/article/icar-dg-balanced-biotech-regulation-for-india-s-farm-sector-e1611c1f35544baaPharma Surgeen2026-07-26T15:15:50.000ZICAR DG: Balanced Biotech Regulation for India''s Farm Sectorhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-nascent-biotech-inc-otc-nbio-9268f6e7308d3c87Pharma Surgeen2026-07-26T14:53:21.000ZEnterprise value to revenue forward of Nascent Biotech Inc. – OTC:NBIOhttps://www.pharmaradar360.com/article/orange-juice-residues-contain-hesperidin-limonene-valencene-and-other-substances-cabeb4fb3777360fPharma Surgeen2026-07-26T14:48:00.000ZOrange juice residues contain hesperidin, limonene, valencene, and other substances that can become a source of valuable compounds for the pharmaceutical and cosmetic industries.https://www.pharmaradar360.com/article/egypt-to-link-drug-prices-to-exchange-rate-and-inflation-4332ff621be073f8Pharma Surgeen2026-07-26T14:38:15.000ZEgypt to link drug prices to exchange rate and inflationhttps://www.pharmaradar360.com/article/fda-panel-backs-6-peptides-in-split-controversial-vote-27e59e4ca77f77c5Pharma Surgeen2026-07-26T14:16:39.000ZFDA panel backs 6 peptides in split, controversial votehttps://www.pharmaradar360.com/article/missing-best-before-dates-at-pune-sweet-shops-raise-consumer-concerns-a9c357805bef51d7Pharma Surgeen2026-07-26T14:04:09.000ZMissing ‘best-before’ dates at Pune sweet shops raise consumer concernshttps://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-l-a-biotech-exec-9e9c1df77595c320Pharma Surgeen2026-07-26T13:18:31.000ZFugitive doctor on run for 21 years was living as L.A. biotech exechttps://www.pharmaradar360.com/article/tiansheng-pharmaceutical-group-co-ltd-class-a-revenue-breakdown-szse-002872-b10d400a05388157Pharma Surgeen2026-07-26T12:10:14.000ZTiansheng Pharmaceutical Group Co. Ltd. Class A Revenue Breakdown – SZSE:002872https://www.pharmaradar360.com/article/labturbo-biotech-corporation-revenue-breakdown-tpex-7725-f60e1b22a23e49fePharma Surgeen2026-07-26T11:33:30.000ZLabTurbo Biotech Corporation Revenue Breakdown – TPEX:7725https://www.pharmaradar360.com/article/arrowhead-pharmaceuticals-arwr-challenges-ionis-ions-with-strong-phase-3-data-in-98ad224f6c6f5b49Pharma Surgeen2026-07-26T10:20:24.000ZArrowhead Pharmaceuticals (ARWR) Challenges Ionis (IONS) With Strong Phase 3 Data In Hypertriglyceridemia Racehttps://www.pharmaradar360.com/article/the-key-to-thriving-in-pharmaceutical-sciences-d8a7d0f5a906fca7Pharma Surgeen2026-07-26T10:18:03.000ZThe Key to Thriving in Pharmaceutical Scienceshttps://www.pharmaradar360.com/article/jyong-biotech-ltd-mens-risk-assessment-volatility-financial-risk-investment-risk-8f0d2ccb119d3c8bPharma Surgeen2026-07-26T10:15:56.000ZJyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Riskhttps://www.pharmaradar360.com/article/charmacy-pharmaceutical-co-ltd-class-h-revenue-breakdown-hkex-2289-7db22e201f9c79c1Pharma Surgeen2026-07-26T09:55:15.000ZCharmacy Pharmaceutical Co., Ltd. Class H Revenue Breakdown – HKEX:2289https://www.pharmaradar360.com/article/amgen-ecovation-how-amgen-builds-sustainability-into-biotech-52bd0d751ed179dcPharma Surgeen2026-07-26T09:47:55.000ZAmgen Ecovation®: How Amgen Builds Sustainability Into Biotechhttps://www.pharmaradar360.com/article/how-polpharma-plans-to-build-a-cee-pharmaceutical-platform-223580291ad8e003Pharma Surgeen2026-07-26T09:43:00.000ZHow Polpharma plans to build a CEE pharmaceutical platformhttps://www.pharmaradar360.com/article/fda-suspends-mumbai-s-rustom-ice-cream-parlour-license-over-food-safety-breaches-71fbd803b9101d3fPharma Surgeen2026-07-26T09:38:25.000ZFDA suspends Mumbai’s ‘Rustom’ ice cream parlour license over food safety breacheshttps://www.pharmaradar360.com/article/us-tariff-proposal-wake-up-call-for-indian-pharma-to-diversify-innovate-experts-cb7b21d166c4fa45Pharma Surgeen2026-07-26T09:32:10.000ZUS tariff proposal wake-up call for Indian pharma to diversify, innovate: Expertshttps://www.pharmaradar360.com/article/innovative-drug-sector-strong-rally-rebound-or-full-reversal-latest-in-depth-fun-ecc93d1767478317Pharma Surgeen2026-07-26T09:22:59.000ZInnovative Drug Sector Strong Rally: Rebound or Full Reversal? Latest In-Depth Fund Manager Judgmentshttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-limited-revenue-breakdown-nse-sunpharma-6cf501cd1c90db56Pharma Surgeen2026-07-26T09:14:11.000ZSun Pharmaceutical Industries Limited Revenue Breakdown – NSE:SUNPHARMAhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-reports-new-phase-3-psoriasis-data-is-the-10-disc-d7b38acc3099460aPharma Surgeen2026-07-26T09:09:17.000ZTakeda Pharmaceutical (TSE:4502) Reports New Phase 3 Psoriasis Data, Is The 10% Discount Enough?https://www.pharmaradar360.com/article/china-pharmaceutical-drying-equipment-market-analysis-forecast-size-trends-and-i-0e77c7a99dbe731aPharma Surgeen2026-07-26T09:05:02.000ZChina Pharmaceutical Drying Equipment - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-tev-q4-2025-earnings-report-results-call-5ab93d80312a256ePharma Surgeen2026-07-26T08:39:35.000ZTeva Pharmaceutical Industries Limited (TEV) Q4 2025 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-s-a-just-missed-eps-by-11-here-s-what-analysts-think-wi-92bbdbf832fc8512Pharma Surgeen2026-07-26T08:27:42.000ZSartorius Stedim Biotech S.A. Just Missed EPS By 11%: Here's What Analysts Think Will Happen Nexthttps://www.pharmaradar360.com/article/tkph4770188-bond-risk-profile-195a5bfa43a80067Pharma Surgeen2026-07-26T08:02:28.000ZTKPH4770188 Bond Risk Profilehttps://www.pharmaradar360.com/article/lawmakers-debate-glp-1-regulation-expansion-5e85630bcf056251Pharma Surgeen2026-07-26T08:01:52.000ZLawmakers debate GLP-1 regulation, expansionhttps://www.pharmaradar360.com/article/judge-rules-fda-restrictions-on-mifepristone-are-arbitrary-and-capricious-2c94ff3098a002e3Pharma Surgeen2026-07-26T07:58:16.000ZJudge rules FDA restrictions on mifepristone are arbitrary and capricioushttps://www.pharmaradar360.com/article/arrowstreet-capital-limited-partnership-purchases-210-112-shares-of-west-pharmac-836348f19fa38c05Pharma Surgeen2026-07-26T07:51:12.000ZArrowstreet Capital Limited Partnership Purchases 210,112 Shares of West Pharmaceutical Services, Inc. $WSThttps://www.pharmaradar360.com/article/consun-pharmaceutical-group-ltd-revenue-breakdown-hkex-1681-d6bd96f03f426e78Pharma Surgeen2026-07-26T07:50:51.000ZConsun Pharmaceutical Group Ltd. Revenue Breakdown – HKEX:1681https://www.pharmaradar360.com/article/orforglipron-news-foundayo-fda-approved-for-weight-loss-4438c6075538dfbaPharma Surgeen2026-07-26T07:41:10.000ZOrforglipron News: Foundayo FDA Approved for Weight losshttps://www.pharmaradar360.com/article/cachet-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-002462-1d81d5b6ce509a8ePharma Surgeen2026-07-26T07:29:33.000ZCachet Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:002462https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-shares-acquired-by-bank-of-nova-scotia-ba5c1d35a8262d94Pharma Surgeen2026-07-26T07:24:34.000ZWest Pharmaceutical Services, Inc. $WST Shares Acquired by Bank of Nova Scotiahttps://www.pharmaradar360.com/article/whan-in-pharmaceutical-co-ltd-revenue-breakdown-krx-016580-80962f1ca25cf58ePharma Surgeen2026-07-26T07:18:37.000ZWhan In Pharmaceutical Co., Ltd. Revenue Breakdown – KRX:016580https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhuhai-rundu-pharmaceutical-co-ltd-class-a-s-54c62203ea9223e4Pharma Surgeen2026-07-26T07:12:49.000ZEnterprise value to EBIT forward of Zhuhai Rundu Pharmaceutical Co. Ltd. Class A – SZSE:002923https://www.pharmaradar360.com/article/the-litmus-study-just-changed-how-you-should-design-your-masld-trial-endpoints-3bb9c82f814d1d09Pharma Surgeen2026-07-26T06:40:51.000ZThe LITMUS Study Just Changed How You Should Design Your MASLD Trial Endpointshttps://www.pharmaradar360.com/article/tak-takeda-pharmaceutical-co-ltd-price-17-240-chg-0-435-40fa51df2325f746Pharma Surgeen2026-07-26T06:22:22.000ZTAK|Takeda Pharmaceutical Co Ltd|Price:17.240|Chg%:+0.435https://www.pharmaradar360.com/article/west-pharmaceutical-stock-holds-recent-gains-as-investors-weigh-steady-growth-an-e12f9c65a03b6e5ePharma Surgeen2026-07-26T05:18:59.000ZWest Pharmaceutical stock holds recent gains as investors weigh steady growth and guidancehttps://www.pharmaradar360.com/article/withus-pharmaceutical-co-ltd-revenue-breakdown-krx-330350-9075c0f60a76345fPharma Surgeen2026-07-26T05:16:26.000ZWITHUS PHARMACEUTICAL Co., Ltd. Revenue Breakdown – KRX:330350https://www.pharmaradar360.com/article/price-to-sales-forward-of-hunan-hansen-pharmaceutical-co-ltd-class-a-szse-002412-bdb55eb1e1cb20d4Pharma Surgeen2026-07-26T05:13:15.000ZPrice to sales forward of Hunan Hansen Pharmaceutical Co., Ltd. Class A – SZSE:002412https://www.pharmaradar360.com/article/west-pharmaceutical-wst-signs-decade-long-daikyo-distribution-deal-beyond-japan-ec1bad39eeaf22a0Pharma Surgeen2026-07-26T05:12:00.000ZWest Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japanhttps://www.pharmaradar360.com/article/sex-specific-safety-signals-of-finerenone-versus-spironolactone-insights-from-th-1e2d878058eb66b8Pharma Surgeen2026-07-26T04:58:00.000ZSex-Specific Safety Signals of Finerenone Versus Spironolactone: Insights From the FDA Adverse Event Reporting Systemhttps://www.pharmaradar360.com/article/outsourcing-formulation-activities-may-advance-drug-development-5944d75d5ad4da59Pharma Surgeen2026-07-26T04:57:04.000ZOutsourcing Formulation Activities May Advance Drug Developmenthttps://www.pharmaradar360.com/article/collegium-pharmaceutical-inc-revenue-breakdown-boats-coll-424549d041650b82Pharma Surgeen2026-07-26T04:31:37.000ZCollegium Pharmaceutical, Inc. Revenue Breakdown – BOATS:COLLhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-zhejiang-hisoar-pharmaceutical-co-ltd-clas-26af6908b515f4f1Pharma Surgeen2026-07-26T04:30:57.000ZEnterprise value to EBITDA forward of Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A – SZSE:002099https://www.pharmaradar360.com/article/amgen-seeks-fda-hearing-files-new-data-to-prevent-tavneos-market-withdrawal-d1cb7b7df4e782a1Pharma Surgeen2026-07-26T04:30:30.000ZAmgen Seeks FDA Hearing, Files New Data to Prevent Tavneos Market Withdrawalhttps://www.pharmaradar360.com/article/takeda-tse-4502-expands-in-indonesia-as-psoriasis-drug-delivers-phase-3-data-52dc52f7ef8b249cPharma Surgeen2026-07-26T04:17:35.000ZTakeda (TSE:4502) Expands In Indonesia As Psoriasis Drug Delivers Phase 3 Datahttps://www.pharmaradar360.com/article/rare-ultragenyx-pharmaceutical-inc-price-26-900-chg-0-120-4ba2abef33a7803dPharma Surgeen2026-07-26T04:16:59.000ZRARE|Ultragenyx Pharmaceutical Inc|Price:26.900|Chg%:-0.120https://www.pharmaradar360.com/article/livzon-pharmaceutical-group-inc-class-h-revenue-breakdown-lsx-a1xcaw-7244ffcfab0f891dPharma Surgeen2026-07-26T03:51:04.000ZLivzon Pharmaceutical Group Inc Class H Revenue Breakdown – LSX:A1XCAWhttps://www.pharmaradar360.com/article/south-korea-s-largest-ever-pharmaceutical-industry-m-a-deal-a-historic-milestone-f372a29e286e1e11Pharma Surgeen2026-07-26T03:12:25.000ZSouth Korea's Largest-Ever Pharmaceutical Industry M&A Deal: A Historic Milestone in the Makinghttps://www.pharmaradar360.com/article/central-pharmaceutical-cpc1-jsc-revenue-breakdown-upcom-dp1-219f0e03e74813aaPharma Surgeen2026-07-26T01:12:36.000ZCentral Pharmaceutical CPC1.JSC Revenue Breakdown – UPCOM:DP1https://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-advances-lead-bitac-r-t-cell-engager-program-with-cel-a351c282a2ef6f46Pharma Surgeen2026-07-26T01:03:15.000ZVERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnershiphttps://www.pharmaradar360.com/article/prnaf-sec-filings-alterity-therapeutics-ltd-10-k-10-q-8-k-forms-32e0d2dcee460616Pharma Surgeen2026-07-26T00:45:27.000ZPRNAF SEC Filings - ALTERITY THERAPEUTICS LTD 10-K, 10-Q, 8-K Formshttps://www.pharmaradar360.com/article/dwwd-etf-profile-dividends-returns-mun-dwwd-7cf3550f22e46273Pharma Surgeen2026-07-26T00:31:09.000ZDWWD ETF Profile: Dividends, Returns (MUN:DWWD)https://www.pharmaradar360.com/article/dxb-phase-3-fsgs-trial-fully-recruited-dmx-652-phase-2-ready-global-deals-up-to-1dc567e3baad824bPharma Surgeen2026-07-26T00:10:00.000ZDXB: Phase 3 FSGS trial fully recruited; DMX-652 phase 2 ready; global deals up to AU$1.9Bhttps://www.pharmaradar360.com/article/clinical-outcomes-following-definitive-concurrent-chemoradiotherapy-in-patients-fc27cf47c83bbb48Pharma Surgeen2026-07-26T00:00:00.000ZClinical Outcomes Following Definitive Concurrent Chemoradiotherapy in Patients With International Federation of Gynecology and Obstetrics (FIGO) Stage IB-IVA Carcinoma of the Cervixhttps://www.pharmaradar360.com/article/orchestrating-modelling-amp-simulation-of-pharmaceutical-production-processes-vi-1d6370a3880d7533Pharma Surgeen2026-07-26T00:00:00.000ZOrchestrating Modelling &amp; Simulation of Pharmaceutical Production Processes Via Large Language Modelshttps://www.pharmaradar360.com/article/role-of-multivariate-data-analyses-in-formulation-and-process-development-of-ora-3c3510df6a686904Pharma Surgeen2026-07-26T00:00:00.000ZRole of Multivariate Data Analyses In Formulation and Process Development of Oral Solid Drug Products: Encapsulation Case Studieshttps://www.pharmaradar360.com/article/a-decade-of-digitizing-pharmaceutical-manufacturing-at-jnj-lessons-learned-and-f-754cecd21ba9815dPharma Surgeen2026-07-26T00:00:00.000ZA Decade of Digitizing Pharmaceutical Manufacturing at JnJ: Lessons Learned and Future Directionshttps://www.pharmaradar360.com/article/pneumobilia-a-clinical-perspective-on-interpretation-and-management-7736a72acaa2c5e5Pharma Surgeen2026-07-26T00:00:00.000ZPneumobilia: A Clinical Perspective on Interpretation and Managementhttps://www.pharmaradar360.com/article/non-steroidal-anti-inflammatory-drug-use-and-the-risk-of-incident-heart-failure-2ea21dcfaa109ec9Pharma Surgeen2026-07-26T00:00:00.000ZNon-Steroidal Anti-Inflammatory Drug Use and the Risk of Incident Heart Failure in Patients with Type 2 Diabetes Mellitus: A Systematic Reviewhttps://www.pharmaradar360.com/article/evaluation-of-drug-utilization-patterns-using-who-indicators-in-patients-with-en-d0358e2f460d6b7cPharma Surgeen2026-07-26T00:00:00.000ZEvaluation of Drug Utilization Patterns Using WHO Indicators in Patients with End-Stage Chronic Kidney Disease: A Cross-Sectional Study in Kirkuk, Iraqhttps://www.pharmaradar360.com/article/lyme-carditis-with-pericarditis-a-review-of-clinical-cases-47c7209d7e11ae42Pharma Surgeen2026-07-26T00:00:00.000ZLyme carditis with pericarditis: A review of clinical caseshttps://www.pharmaradar360.com/article/mesenchymal-stem-cell-derived-extracellular-vesicles-as-next-generation-drug-del-a2ebad1887074d8ePharma Surgeen2026-07-26T00:00:00.000ZMesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platformshttps://www.pharmaradar360.com/article/clinical-significance-of-mesenchymal-stem-cells-exosomal-micrornas-in-predicting-d43f76f9e474ca1dPharma Surgeen2026-07-26T00:00:00.000ZClinical significance of mesenchymal stem cells exosomal microRNAs in predicting prognosis and inflammatory response of esophageal cancerhttps://www.pharmaradar360.com/article/mechanistic-insights-into-honeybee-propolis-as-a-natural-modulator-of-inflammati-6f3ef953864efabfPharma Surgeen2026-07-26T00:00:00.000ZMechanistic Insights into Honeybee Propolis as a Natural Modulator of Inflammation and Oxidative Stress: A Narrative Reviewhttps://www.pharmaradar360.com/article/in-vitro-evaluation-of-antioxidant-activity-and-tyrosinase-inhibition-of-syzygiu-0600f715b3aa7078Pharma Surgeen2026-07-26T00:00:00.000ZIn Vitro Evaluation of Antioxidant Activity and Tyrosinase Inhibition of Syzygium polyanthum Extracthttps://www.pharmaradar360.com/article/prunasin-alleviates-ogd-r-induced-injury-in-h9c2-cardiomyocytes-via-src-egfr-akt-44fe2006be98e1e1Pharma Surgeen2026-07-26T00:00:00.000ZPrunasin alleviates OGD/R-induced injury in H9c2 cardiomyocytes via SRC/EGFR-AKT-FoxO-mediated mitochondrial quality controlhttps://www.pharmaradar360.com/article/astragaloside-iv-attenuates-high-glucose-induced-podocyte-ferroptosis-via-the-gs-26666fa473cf2721Pharma Surgeen2026-07-26T00:00:00.000ZAstragaloside IV attenuates high glucose-induced podocyte ferroptosis via the GSK3?/Nrf2/GPX4 pathwayhttps://www.pharmaradar360.com/article/duo-nang-decoction-enhances-endometrial-receptivity-in-pcos-rats-by-upregulating-cc0bf35c2fb30077Pharma Surgeen2026-07-26T00:00:00.000ZDuo Nang Decoction enhances endometrial receptivity in PCOS rats by upregulating caveolin-1 expressionhttps://www.pharmaradar360.com/article/clinical-profiles-risk-factors-and-management-outcomes-of-ectopic-pregnancy-atte-4945fc67accc52eePharma Surgeen2026-07-26T00:00:00.000ZClinical Profiles, Risk Factors and Management Outcomes of Ectopic Pregnancy attended at a Tertiary Care Hospital in Bangladeshhttps://www.pharmaradar360.com/article/clinical-characteristics-precipitating-factors-in-hospital-management-and-30-day-3d3046bdeeb3564bPharma Surgeen2026-07-26T00:00:00.000ZClinical Characteristics, Precipitating Factors, In-Hospital Management, and 30-Day Outcomes of Patients Hospitalized with Acute Decompensated Heart Failure: A Single-Center Study from Vietnamhttps://www.pharmaradar360.com/article/overlapping-pathological-features-of-alzheimer-s-and-parkinson-s-diseases-clinic-f5b28d38a424e95ePharma Surgeen2026-07-26T00:00:00.000ZOverlapping pathological features of Alzheimer’s and Parkinson’s diseases: Clinical implications and future directions for improving diagnostic precisionhttps://www.pharmaradar360.com/article/herbal-drug-adulteration-a-threat-to-safety-efficacy-and-global-herbal-trade-22fef03aa8dbb793Pharma Surgeen2026-07-26T00:00:00.000ZHerbal Drug Adulteration: A Threat to Safety, Efficacy, and Global Herbal Tradehttps://www.pharmaradar360.com/article/intradural-extramedullary-formation-in-a-pregnant-woman-a-clinical-case-590b68942c72cda7Pharma Surgeen2026-07-26T00:00:00.000ZIntradural extramedullary formation in a pregnant woman: a clinical casehttps://www.pharmaradar360.com/article/lhermitte-duclos-disease-rare-clinical-case-9ea7e124b3e8988fPharma Surgeen2026-07-26T00:00:00.000ZLhermitte-Duclos disease: rare clinical casehttps://www.pharmaradar360.com/article/psychogenic-non-epileptic-seizures-in-pediatric-neurosurgical-patients-with-drug-958afa8bfa952872Pharma Surgeen2026-07-26T00:00:00.000ZPsychogenic non-epileptic seizures in pediatric neurosurgical patients with drug-resistant epilepsyhttps://www.pharmaradar360.com/article/feasibility-of-using-a-patient-portal-to-recruit-latino-adults-into-a-smoking-ce-50cd680715f04782Pharma Surgeen2026-07-26T00:00:00.000ZFeasibility of using a patient portal to recruit Latino adults into a smoking cessation and physical activity randomized clinical trial: A secondary analysishttps://www.pharmaradar360.com/article/correction-to-spontaneous-fracture-of-a-titanium-mesh-cranioplasty-implant-in-a-fa09bf0804c10563Pharma Surgeen2026-07-26T00:00:00.000ZCorrection to “Spontaneous fracture of a titanium mesh cranioplasty implant in a child: A case report”https://www.pharmaradar360.com/article/fish-oil-emulsion-for-reversal-of-intestinal-failure-associated-liver-disease-in-e8821df9bdfb2f68Pharma Surgeen2026-07-26T00:00:00.000ZFish oil emulsion for reversal of intestinal failure-associated liver disease in preterm infants: Three case reports and review of literaturehttps://www.pharmaradar360.com/article/decoding-the-glycemic-paradox-the-imperative-for-frailty-centered-inpatient-diab-811e9a73b5acecddPharma Surgeen2026-07-26T00:00:00.000ZDecoding the glycemic paradox: The imperative for frailty-centered inpatient diabetes carehttps://www.pharmaradar360.com/article/dickkopf-1-in-rheumatoid-arthritis-mechanistic-insights-imaging-associations-and-deabfa656ba9e7c3Pharma Surgeen2026-07-26T00:00:00.000ZDickkopf-1 in rheumatoid arthritis: Mechanistic insights, imaging associations, and emerging therapeutic strategieshttps://www.pharmaradar360.com/article/wilson-s-disease-in-children-recent-update-on-pathophysiology-and-management-b31544a43d24167dPharma Surgeen2026-07-26T00:00:00.000ZWilson’s disease in children: Recent update on pathophysiology and managementhttps://www.pharmaradar360.com/article/limited-transscleral-cyclophotocoagulation-for-silicone-oil-induced-glaucoma-in-20bd908c2bafaafcPharma Surgeen2026-07-26T00:00:00.000ZLimited transscleral cyclophotocoagulation for silicone oil-induced glaucoma in eyes with good visual potentialhttps://www.pharmaradar360.com/article/aspiration-of-a-metallic-crowned-tooth-in-the-left-main-bronchus-in-a-neurocriti-7586522aed69a82dPharma Surgeen2026-07-26T00:00:00.000ZAspiration of a metallic-crowned tooth in the left main bronchus in a neurocritical patient: A case reporthttps://www.pharmaradar360.com/article/rectal-mantle-cell-lymphoma-endoscopically-mimicking-ulcerative-proctitis-a-case-d6737d164ffab75cPharma Surgeen2026-07-26T00:00:00.000ZRectal mantle cell lymphoma endoscopically mimicking ulcerative proctitis: A case reporthttps://www.pharmaradar360.com/article/phase-ii-multicenter-clinical-trial-of-intraoperative-molecular-imaging-with-abe-8c9457100c005e40Pharma Surgeen2026-07-26T00:00:00.000ZPhase II Multicenter Clinical Trial of Intraoperative Molecular Imaging with Abenacianine During Lung Cancer Surgeryhttps://www.pharmaradar360.com/article/early-prediction-of-intensive-care-unit-acquired-weakness-using-quadriceps-ultra-bd1ace49132c8a96Pharma Surgeen2026-07-26T00:00:00.000ZEarly prediction of intensive care unit-acquired weakness using quadriceps ultrasound and routine clinical variables: development and temporal validation of a prospective multicentre machine-learning modelhttps://www.pharmaradar360.com/article/factors-influencing-the-acceptability-of-remote-multicomponent-rehabilitation-ve-b24053bd3dde07c0Pharma Surgeen2026-07-26T00:00:00.000ZFactors influencing the acceptability of remote multicomponent rehabilitation versus standard care following critical illness: a theory-informed qualitative study embedded within the iRehab trialhttps://www.pharmaradar360.com/article/proteomic-insights-in-sepsis-advancing-diagnosis-therapeutic-targets-and-the-pat-5c0de7ea8a9d415bPharma Surgeen2026-07-26T00:00:00.000ZProteomic insights in sepsis: advancing diagnosis, therapeutic targets, and the path to precision medicinehttps://www.pharmaradar360.com/article/life-stage-specific-hematological-profiles-in-yellow-mealworm-beetles-i-tenebrio-5278bb9c0d386167Pharma Surgeen2026-07-26T00:00:00.000ZLife‐Stage–Specific Hematological Profiles in Yellow Mealworm Beetles ( <i>Tenebrio molitor</i> ): Reference Intervals and Hemocyte Characterizationhttps://www.pharmaradar360.com/article/the-forgotten-history-of-semi-implanted-radiofrequency-and-inductive-powered-car-eaec77e0c590452fPharma Surgeen2026-07-26T00:00:00.000ZThe Forgotten History of Semi‐Implanted Radiofrequency‐ and Inductive‐Powered Cardiac Pacing Systemshttps://www.pharmaradar360.com/article/contact-index-for-pulseselect-catheter-apposition-validation-by-transesophageal-76a053877d9506e6Pharma Surgeen2026-07-26T00:00:00.000ZContact Index for PulseSelect Catheter Apposition: Validation by Transesophageal Echocardiographyhttps://www.pharmaradar360.com/article/variability-in-pacemaker-battery-estimates-and-performance-0efeb3542e7cf41ePharma Surgeen2026-07-26T00:00:00.000ZVariability in Pacemaker Battery Estimates and Performance